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Dendritic Epidermal T Cells (DETC) are Diminished in
Integrin aE(CD103)-De®cient Mice
To the Editor:
A unique cell population of Thy-1+ dendritic epidermal cells
resides within murine epidermis (Bergstresser et al, 1983;
Tschachler et al, 1983). When it was recognized that this
population belongs to the lineage of gdTCR+ T lymphocytes,
they were named dendritic epidermal T cells (DETC) (Koning et
al, 1987; Kuziel et al, 1987; Stingl et al, 1987a; 1987b). DETC
exhibit a very limited diversity of TCR g and d gene usage with
very little junctional diversity, and most, if not all, bear the TCR
Vg3-Jg1-Cg1/Vd1-Dd2-Jd2-Cd (Asarnow et al, 1988, 1989;
Havran and Allison, 1988; Havran et al, 1989). Thymic origin of
DETC was strongly suggested by the observation that TCR-Vg3+
thymocytes [nomenclature according to Garman et al equivalent to
the Vg5 designation by Tonegawa and Heilig (Hayday and Pao,
1998)] appear at days 14±15 of gestational life, and disappear from
the thymus before their ®rst appearance within the epidermis at
days 17±19 of gestation (Havran and Allison, 1988). In addition,
implantation of day-14 thymic lobes from normal mice into
athymic nude mice (which lack Vg3+ DETC) resulted in the
appearance of an epidermal CD3+/Vg3+ population of DETC
(Havran and Allison, 1990). Whereas some experimental evidence
suggested that DETC participate in tolerance induction, elicitation
of contact hypersensitivity, tumor rejection, and other immuno-
logic functions (Tigelaar and Lewis, 1995; Girardi et al, 2001),
many aspects of their biologic role remain unknown. More
recently, it was found that integrin aE(CD103)b7 is expressed
around day 16 of gestation by TCR-Vg3+ thymocytes, and it was
hypothesized that this adhesion receptor is involved in epidermal
localization of DETC (Lefrancois et al, 1994). This suggestion was
consistent with the known functions of aE(CD103)b7 on intestinal
intraepithelial T lymphocytes, where it mediates adhesion to the
epithelial cell surface molecule E-cadherin (Cepek et al, 1994;
Karecla et al, 1995), a counter-receptor that is also constitutively
expressed by epidermal keratinocytes (Takeichi, 1990). Recently,
we demonstrated that aE(CD103)b7 mediates, at least in part,
epidermal localization of some CD8+ T lymphocytes in human
in¯ammatory skin disorders. This was based primarily upon
antibody-mediated blocking of adhesive functions of cultured T
lymphocytes expressing aE(CD103)b7 (Pauls et al, 2001). There is
no experimental evidence thus far, however, supporting the
hypothesis that integrin aE(CD103)b7 is involved in epidermal
localization of murine DETC.
In order to directly investigate the effect of integrin aE(CD103)
on DETC in vivo, we have analyzed wildtype mice and mice
lacking expression of the aE(CD103) integrin subunit, whose
generation and characterization was described recently (SchoÈn et al,
1999, 2000). Given that considerable strain-dependent differences
in the numbers of DETC have been reported, and as BALB/c mice
(the strain in which the aE-de®cient mice were ®rst generated)
have signi®cantly fewer DETC than other inbred strains
(Bergstresser et al, 1983), the aE(CD103)-de®cient animals were
backcrossed for ®ve to seven generations into the C57BL/6 strain
and then analyzed for DETC number.
In our initial experiments, the presence of DETC within the
epidermis was assessed by immunohistochemical analysis (ABC
immunoperoxidase method according to the manufacturer's
instructions; Vector, Burlingame, CA) using monoclonal antibodies
speci®c for CD3e (clone 500A), integrin aE(CD103) (clone 2E7),
TCR Vg3 (clone 536), and an isotype-matched control mono-
clonal antibody (clone Ha4/8, hamster IgGk monoclonal anti-
bodies purchased from PharMingen, San Diego, CA). As expected,
aE(CD103) was not expressed in the skin of aE(CD103)-de®cient
mice, whereas it was readily detected on numerous cells of
dendritic morphology within the epidermis of wildtype (aE+/+)
mice (Fig 1). Interestingly, when CD3+/Vg3+ DETC were
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quantitated within the epidermis of wildtype mice and aE±/±
littermates, the number of DETC was reduced signi®cantly by 68%
in aE±/± mice (6.05 DETC per mm epidermis, SD = 1.40, n = 6)
compared to their wildtype littermates (18.83 DETC per mm
epidermis, SD = 4.39, n = 6, p < 0.0005, Fig 1).
A reduced number of DETC was also observed in aE±/± mice on
the BALB/c genetic background, in which wildtype animals had
1.23 DETC per mm epidermis (SD = 0.11, n = 3), as opposed to
only 0.53 DETC per mm epidermis (SD = 0.15, n = 3) in aE-
de®cient mice, demonstrating a signi®cant reduction of DETC by
57% (p = 0.04). Thus, there were reduced numbers of DETC in
aE-de®cient mice compared to wildtype animals in two genetically
distinct inbred strains of mice, as detected by immunohistochem-
istry.
In order to con®rm and extend these results by a second method,
¯ow cytometric analyses were performed. Towards this end,
epidermal cell suspensions from ear skin of aE+/+ and aE±/± mice of
the C57BL/6 genetic background were generated and analyzed on
a FACScan ¯ow cytometer (Becton Dickinson, San Diego, CA).
Brie¯y, mouse ears were incubated with dispase (grade II;
Boehringer Mannheim, Germany) at 6 mg per ml for 60 min at
37°C. Thereafter, the epidermal sheets were easily peeled off the
ear tissue and digested again for 5 min under gentle stirring at 37°C
in a solution containing 6 mg per ml dispase and 10 ml per ml of
0.1% DNase. The resulting single-cell suspension of epidermal cells
Figure 1. DETC are signi®cantly diminished
in the skin of integrin aE(CD103)-de®cient
mice. (A) Cryostat-cut sections of ear skin from a
wildtype mouse of the C57BL/6 genetic back-
ground and an aE(CD103)-de®cient littermate
(backcrossed for six generations) were stained by
the immunoperoxidase method for aE(CD103)
and CD3e as indicated. Scale bar: 20 mm. The
tissues depicted are representative for six mice
of each genotype. (B) CD3+ DETC were
quantitated in the skin of C57BL/6 wildtype
(left bar) and aE(CD103)-de®cient (right bar) mice.
Values shown represent average numbers of
cells (6 SD) in six animals of each genotype.
*p < 0.0005.
Figure 2. Diminished population of CD3+ DETC in epidermal
cell suspensions from aE(CD103)-de®cient mice. Epidermal cell
suspensions of ear skin from a wildtype (left panel) and an aE(CD103)-
de®cient mouse (right panel) of the C57BL/6 genetic background
(backcrossed for six generations) were subjected to two-color FACS
analysis using monoclonal antibodies speci®c for CD3 (phycoerythrin)
and aE(CD103) (¯uorescein isothiocyanate) as outlined in the text. Dead
cells were excluded by propidium iodide staining. CD3+ cells are located
in the upper quadrants of the dot plots. Numbers indicate percentages of
the CD3+ cells. The experiment shown is representative of ®ve
independent experiments. Note reduced numbers of CD3+ epidermal
cells and lack of aE(CD103) on aE-de®cient cells.
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was then subjected to two-color ¯uorescence-activated cell sorter
(FACS) analysis using monoclonal antibodies speci®c for
aE(CD103), CD3e, and TCR-Vg3 as outlined above. As expected,
no cell surface expression of aE(CD103) was detected on cells
derived from aE(CD103)-de®cient mice. When the proportion of
CD3+/TCR-Vg3+ DETC within the epidermal cell suspensions
was assessed by two-color FACS, it was found that DETC were
signi®cantly reduced to 52% of wildtype levels (mean = 1.8%,
range 1.3%±2.6%, 60.48) in the aE(CD103)-de®cient material
compared to the wildtype cell suspensions (mean 3.9%, range
2.6%±5.1%, 6 1.08; reduction in aE±/± animals compared to
wildtype mice between 29% and 84%, p < 0.04, Fig 2). These
results were obtained in ®ve independent experiments, four of
which were performed using littermate control mice. Preliminary
data suggested that heterozygous (aE+/±) animals had intermediate
numbers of CD3+/TCR-Vg3+ epidermal cells, as in one experi-
ment an aE(CD103)-de®cient mouse had 1.5% DETC, two
heterozygous littermates had 2.6% and 2.7% DETC, respectively,
and a wildtype littermate had 4.9% DETC (data not shown). These
data were consistent with the previous observation that integrin
aE(CD103) is expressed at intermediate levels on T lymphocytes of
heterozygous animals (SchoÈn et al, 1999), and con®rmed the
marked reduction of DETC in aE(CD103)-de®cient mice detected
by our initial immunohistochemical analysis. Of note, DETC
detected in aE(CD103)-de®cient mice were similar to those of
wildtype animals as they expressed Vg3 and CD2 but not abTCR,
NK1.1, CD4, and CD8 (data not shown). This was in contrast to
DETC in Vd1- or Vg3-de®cient mice in which gdT cells
expressing a different gdTCR apparently replaced the ``normal''
DETC, at least in part (Malick-Wood et al, 1998; Hara et al, 2000).
To assess whether aE de®ciency might also affect Langerhans cells,
another dendritic cell population within the epidermis that interacts
with keratinocytes via E-cadherin, an additional experiment was
performed in which the numbers of epidermal CD45+/I-Ab+ cells
(major histocompatibility complex class II+ as a marker for
epidermal Langerhans cells in mice) were assessed in an
aE(CD103)-de®cient mouse and a heterozygous [aE(CD103)+/±]
littermate. It was found that CD45+/I-Ab+ cells accounted for 4.3%
of epidermal cells in the aE-de®cient animal and 3.5% in the
heterozygous littermate, suggesting that aE de®ciency did not
reduce the number of epidermal Langerhans cells (data not shown).
Overall, the signi®cantly diminished number of DETC within
the epidermis of aE(CD103)-de®cient mice compared to their
wildtype littermates supports the hypothesis that aE(CD103)b7
mediates, at least in part, epidermal localization of murine TCR-
Vg3+ DETC. Considering the known functions of the integrin
aE(CD103)b7, however, several molecular mechanisms could
potentially underlie the altered DETC numbers in aE(CD103)-
de®cient mice, which are not mutually exclusive. First, aE(CD103)
may directly mediate epidermal localization or retention of
circulating TCR-Vg3+ thymocytes (Havran and Allison, 1988,
1990; Lefrancois et al, 1994) via its known adhesive interaction with
epidermal E-cadherin (Cepek et al, 1994; Karecla et al, 1995). This
hypothesis is supported by our recent observation that integrin
aE(CD103)b7 directly mediates epidermal adhesive interactions of
some human CD8+ T lymphocytes in modi®ed Stamper±
Woodruff assays as well as in experiments assessing adhesion of T
cells to cultured keratinocytes (Pauls et al, 2001). Second,
aE(CD103)-bearing TCR-Vg3+ thymocytes may bind to an as
yet unknown alternative ligand expressed by other cutaneous cell
types, similar to mechanisms that were recently suggested for
keratinocytes (Brown et al, 1999) and intestinal microvascular
endothelial cells (Strauch et al, 2001). Third, de®ciency of
aE(CD103) may result in altered thymic development of the
Vg3+ thymocyte population during fetal development. There is no
experimental evidence for the latter two hypotheses, however.
Fourth, aE(CD103)b7 could be involved in regulating DETC
proliferation or death. There is some circumstantial evidence
supporting this hypothesis, as some anti-aE monoclonal antibodies
enhance proliferation of cultured T cells in response to suboptimal
concentrations of anti-CD3 (Lefrancois et al, 1994; Russell et al,
1994). Finally, de®ciency of aE(CD103) may result in compensa-
tory changes of other adhesion receptors, which could account for
altered epidermal localization of TCR-Vg3+ thymocytes as a
secondary phenomenon. This possibility appears unlikely, how-
ever, as no signi®cant alterations of many other adhesion molecules
could be detected on gut derived intraepithelial T lymphocytes in
aE(CD103)-de®cient mice (SchoÈn et al, 1999). Although our
results imply an important role of integrin aE(CD103) in regulating
murine TCR-Vg3+ DETC numbers, additional molecular mech-
anisms appear to exist, as DETC are also present, albeit in reduced
numbers, in the epidermis of aE(CD103)-de®cient mice. As the
known ligand for aE(CD103)b7, E-cadherin, is widely distributed
in various epithelia, it is not completely clear to what extent the
integrin aE(CD103) contributes to epidermis-speci®c localization
of DETC or whether some Vg3+ T cells might localize to other
epithelia in the absence of aE(CD103). In any case, our results
provide the ®rst in vivo evidence that expression of aE(CD103)
signi®cantly in¯uences the presence of CD3+/Vg3+ DETC within
murine epidermis.
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T Cell Receptor-Vb Analysis Identi®es a Dominant
CD60+ CD26± CD49d± T Cell Clone in the Peripheral Blood
of SeÂzary Syndrome Patients
To the Editor:
Clonality assessment of T cell leukemias has widely been detected
by several molecular techniques such as southern blotting analysis
and polymerase chain reaction (PCR), mostly on T cell receptor
(TCR)-g genes, but also TCR-b due to its larger recombination
variable region repertoire. TCR-Vb ¯uorescence-activated cell
sorter (FACS) analysis has also been used recently for the assessment
of clonality in T cell malignancies (Gorochov et al, 1995; Bigler et al,
1996; Rappl et al, 2001).
In this study we employed FACS TCR-Vb repertoire analysis in
13 patients with SeÂzary syndrome (SS), using a panel of 21
monoclonal antibodies (MoAb) covering 70% of the entire human
Vb repertoire. Ten of these patients showed a single Vb
population, ranging from 67 to 99%, of circulating CD4+ T cells.
This restricted reactivity concerned several TCR-Vb families;
however, expansion of Vb 2 was observed in four cases and Vb 5.1
in two cases (Table I).
To establish if the expanded TCR-Vb T cell population seen by
¯ow cytometry was due to a homogeneous T cell clone, we further
analyzed the diversity of the T cell repertoire through molecular
techniques such as spectratyping and direct sequencing. We took
advantage of the previous FACS analysis (Fig 1A) to run single
speci®c reverse transcription±PCR on RNA extracted from each
sample. We were able to show speci®c ampli®cation for the
corresponding TCR-Vb genes by either agarose gel analysis or by
spectratyping (Fig 1B,C). The use of spectratyping easily con-
®rmed the clonality within the Vb-positive clone, leaving out the
possibility of a polyclonal population, as this technique measures
the size heterogeneity of the TCR hypervariable CDR3 region.
The spectratypes obtained from normal repertoires are complex and
show a Gaussian distribution of eight or more bands that represent
the different lengths of the respective TCR VDJ regions. By
contrast, CDR3 size analysis from patients affected by SS contained
only one dominant peak, which is highly suggestive of a clonal
expansion (Fig 1B) (Bagot et al, 1998). The PCR product was
further sequenced and compared with a TCR-Vb database (Folch
et al, 2000) con®rming that they were speci®cally rearranged Vb
(Fig 1D). These molecular approaches con®rmed the clonality of
the restricted population identi®ed in 10 of 13 patients by FACS
analysis and allowed also the possibility to design speci®c primers
for each individual patient. We did not observe multiple reactions
to TCR-Vb MoAb.
We performed FACS Vb analysis in the 10 positive patients
6 mo after the ®rst analysis. In two cases we observed a marked
reduction in circulating TCR-Vb reactive cells associated with a
clinical improvement (clearing of palmoplantar hyperkeratosis, 90%
reduction of erythroderma, loss of dermal edema, scaling,
lymphoadenopathy, and disappearance of pruritus) during treat-
ment with extracorporeal photopheresis (on two consecutive days,
monthly) and a2a recombinant interferon (Fig 2). These data
clearly indicate that Vb FACS analysis might be useful for the
measurement of the tumor burden. A major advantage of ¯ow
cytometry TCR-Vb analysis over molecular analysis is that the Vb
restricted T cell population can quantitatively be monitored during
and after therapy, as shown in Fig 2, and be applied also in
laboratories lacking molecular biology techniques.
We then took advantage of the speci®c Vb reactivity of these
neoplastic T cells in SS to de®ne the phenotype of these cells. We
used several markers that have been associated with these malignant
cells (Dummer et al, 1999; Bernengo et al, 2001; Jones et al, 2001;
Rappl et al, 2001). We found that the expression of CD60, the lack
of CD26, and, to a lesser extent, the lack of CD49d were invariably
associated with the expanded Vb clones. Heterogeneity was instead
observed in the expression of CD7 and CLA among different cases
(see Table I), as previously described (Bernengo et al, 2001;
Dummer et al, 1999; Jones et al, 2001), whereas other surface
antigens studied, such as CD27, CD28, CD70, and CD103, were
not signi®cantly associated with the clonal T cells (not shown).
CD45R0 was expressed by all T cells despite their Vb positivity.
When normal individuals were studied for the CD4+ CD26±
CD49d± CD60+ phenotype, we found such phenotype in less than
5% of circulating T cells. Thus, the expansion of such a population
in the peripheral blood of SS patients might have a functional
signi®cance. It is well known, in fact, that neoplastic cells of SS
patients do not grow in vitro, either spontaneously or when
challenged with standard proliferative stimuli (McCusker et al,
1997; Harwix et al, 2001). By contrast, in vitro challenge of T cells
from patients with cutaneous T cell lymphoma with anti-CD60
results in frank activation of these cells suggesting that this antigen-
independent activation pathway might also be important in vivo
(Hansen et al, 1993). On the other hand, the simultaneous lack of
CD26 and CD49d surface antigens might be associated with the
loss of epidermotropism of cutaneous T cell lymphoma clones in
patients who have hematologic involvement, as both these
molecules exert adhesion activities with the extracellular matrix.
Peripheral T cells migrating through a layer of endothelial cells on
collagen, express very high levels of CD26 (Masuyama et al, 1992),
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